The U.S. Food and Drug Administration (FDA) is now releasing complete response letters (CRLs) for BLA and NDA products not yet approved – including CRLs associated with pending or withdrawn applications. ...more
9/5/2025
/ Biologics ,
Disclosure Requirements ,
Executive Orders ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
Life Sciences ,
Pharmaceutical Industry ,
Regulatory Oversight ,
Regulatory Requirements ,
Trade Secrets ,
Transparency